Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1080/15548627.2015.1017185

http://scihub22266oqcxt.onion/10.1080/15548627.2015.1017185
suck pdf from google scholar
C4824600!4824600 !25893854
unlimited free pdf from europmc25893854
    free
PDF from PMC    free
html from PMC    free

Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25893854 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215

suck abstract from ncbi

pmid25893854
      Autophagy 2015 ; 11 (10 ): 1849-63
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Elaiophylin, a novel autophagy inhibitor, exerts antitumor activity as a single agent in ovarian cancer cells #MMPMID25893854
  • Zhao X ; Fang Y ; Yang Y ; Qin Y ; Wu P ; Wang T ; Lai H ; Meng L ; Wang D ; Zheng Z ; Lu X ; Zhang H ; Gao Q ; Zhou J ; Ma D
  • Autophagy 2015[]; 11 (10 ): 1849-63 PMID25893854 show ga
  • Currently, targeting the autophagic pathway is regarded as a promising new strategy for cancer drug discovery. Here, we screened the North China Pharmaceutical Group Corporation's pure compound library of microbial origin using GFP-LC3B-SKOV3 cells and identified elaiophylin as a novel autophagy inhibitor. Elaiophylin promotes autophagosome accumulation but blocks autophagic flux by attenuating lysosomal cathepsin activity, resulting in the accumulation of SQSTM1/p62 in various cell lines. Moreover, elaiophylin destabilizes lysosomes as indicated by LysoTracker Red staining and CTSB/cathepsin B and CTSD/ cathepsin D release from lysosomes into the cytoplasm. Elaiophylin eventually decreases cell viability, especially in combination with cisplatin or under hypoxic conditions. Furthermore, administration of a lower dose (2 mg/kg) of elaiophylin as a single agent achieves a significant antitumor effect without toxicity in an orthotopic ovarian cancer model with metastasis; however, high doses (8 mg/kg) of elaiophylin lead to dysfunction of Paneth cells, which resembles the intestinal phenotype of ATG16L1-deficient mice. Together, these results provide a safe therapeutic window for potential clinical applications of this compound. Our results demonstrate, for the first time, that elaiophylin is a novel autophagy inhibitor, with significant antitumor efficacy as a single agent or in combination in human ovarian cancer cells, establishing the potential treatment of ovarian cancer by this compound.
  • |Animals [MESH]
  • |Antineoplastic Agents/pharmacology [MESH]
  • |Autophagy/*drug effects [MESH]
  • |Cell Line, Tumor [MESH]
  • |Cell Survival/drug effects [MESH]
  • |Female [MESH]
  • |Humans [MESH]
  • |Lysosomes/*drug effects/metabolism [MESH]
  • |Macrolides/*pharmacology [MESH]
  • |Mice [MESH]
  • |Ovarian Neoplasms/*drug therapy/pathology [MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box